Winnipeg, Manitoba, Canada
Desmoid tumours are rare, non-metastasizing soft tissue tumours that can be locally aggressive and challenging to treat. Pegylated Liposomal Doxorubicin (PLD) is a chemotherapeutic formulation that has been proposed as a potential treatment for these tumours due to its favorable toxicity profile and sustained drug release. My project focused on evaluating the clinical outcomes and treatment response of desmoid tumour patients receiving PLD, as part of a broader CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) study. Specifically, I contributed to a retrospective chart review and clinical data collection, assessing treatment efficacy, adverse events, and long-term patient outcomes. This work is a sub-study of the larger CanSaRCC initiative, titled “Clinical Outcome and Genetic Analysis of Sarcoma”, supervised by Dr. Sapna Oberoi. I worked alongside a multidisciplinary team, gaining exposure to both clinical oncology and translational sarcoma research.
Desmoid tumours are rare, non-metastasizing soft tissue tumours that can be locally aggressive and challenging to treat. Pegylated Liposomal Doxorubicin (PLD) is a chemotherapeutic formulation that has been proposed as a potential treatment for these tumours due to its favorable toxicity profile and sustained drug release. My project focused on evaluating the clinical outcomes and treatment response of desmoid tumour patients receiving PLD, as part of a broader CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) study. Specifically, I contributed to a retrospective chart review and clinical data collection, assessing treatment efficacy, adverse events, and long-term patient outcomes. This work is a sub-study of the larger CanSaRCC initiative, titled “Clinical Outcome and Genetic Analysis of Sarcoma”, supervised by Dr. Sapna Oberoi. I worked alongside a multidisciplinary team, gaining exposure to both clinical oncology and translational sarcoma research.
Toronto General Hospital, Toronto Western Hospital, Princess Margaret Cancer Centre, Toronto Rehabilitation Institute, The Michener Institute of Education at UHN and West Park Healthcare Centre Project title: Clinical Outcome and Genetic Analysis of Sarcoma [CanSarCC] Sub-Study: Pegylated Liposomal Doxorubicin for the Treatment of Desmoid Tumour: A Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) Study
The Canadian Sarcoma Research and Clinical Collaboration (CanSaRCC) is a national research Registry initiative aimed at improving the understanding, treatment, and outcomes of sarcoma patients across Canada. It brings together a network of clinicians, researchers, and patient advocates focused on generating high-quality, real-world evidence to inform best practices in sarcoma care. Through collaborative clinical studies, genetic analyses, and long-term follow-up, CanSaRCC supports both retrospective and prospective research into a wide range of sarcoma subtypes, including rare and difficult-to-treat tumours like desmoid tumours. The initiative emphasizes patient-centered care, data sharing, and innovation in treatment strategies to drive meaningful advances in sarcoma research and management. Desmoid tumours are rare, non-metastasizing soft tissue tumours that can be locally aggressive and challenging to treat. Pegylated Liposomal Doxorubicin (PLD) is a chemotherapeutic formulation that has been proposed as a potential treatment for these tumours due to its favorable toxicity profile and sustained drug release. My project focused on evaluating the clinical outcomes and treatment response of desmoid tumour patients receiving PLD, as part of a broader CanSaRCC (Canadian Sarcoma Research and Clinical Collaboration) study. Specifically, I contributed to a retrospective chart review and clinical data collection, assessing treatment efficacy, adverse events, and long-term patient outcomes. This work is a sub-study of the larger CanSaRCC initiative, titled “Clinical Outcome and Genetic Analysis of Sarcoma”, supervised by Dr. Sapna Oberoi. I worked alongside a multidisciplinary team, gaining exposure to both clinical oncology and translational sarcoma research.
As a recreation student at the Simkin Center in Winnipeg, Manitoba, my role is integral to enhancing the overall well-being and quality of life for the residents. My primary responsibility involves planning and implementing recreational activities that cater to the diverse needs and interests of the individuals in your care. In this role, we all collaborate with fellow staff members to create a vibrant and engaging activity program. This may include organizing group events, outings, and in-house activities that promote social interaction, cognitive stimulation, and physical well-being.